Related Experiment Video
Updated: Jul 4, 2026

Bilateral Common Carotid Artery Occlusion as an Adequate Preconditioning Stimulus to Induce Early Ischemic Tolerance to Focal Cerebral Ischemia
Published on: May 9, 2013
Glycogen synthase kinase-3 inactivation is not required for ischemic preconditioning or postconditioning in the mouse
Yasuhiro Nishino1, Ian G Webb, Sean M Davidson
1King's College London BHF Centre, Cardiovascular Division, The Rayne Institute, St. Thomas' Hospital, UK.
Abstract:
The inactivation of glycogen synthase kinase-3beta (GSK-3beta) is proposed as the event integrating protective pathways initiated by preconditioning and other interventions. The inactivation of GSK-3 is thought to decrease the probability of opening of the mitochondrial permeability transition pore. The aim of this study was to verify the role of GSK-3 using a targeted mouse line lacking the critical N-terminal serine within GSK-3beta (Ser9) and the highly homologous GSK-3alpha (Ser21), which when phosphorylated results in kinase inactivation. Postconditioning with 10 cycles of 5 seconds of reperfusion/5 seconds of ischemia and preconditioning with 6 cycles of 4 minutes of ischemia/6 minutes of reperfusion, similarly reduced infarction of the isolated perfused mouse heart in response to 30 minutes of global ischemia and 120 minutes of reperfusion. Preconditioning caused noticeable inactivating phosphorylation of GSK-3. However, both preconditioning and postconditioning still protected hearts of homozygous GSK-3 double knockin mice. Moreover, direct pharmacological inhibition of GSK-3 catalytic activity with structurally diverse inhibitors before or after ischemia failed to recapitulate conditioning protection. Nonetheless, cyclosporin A, a direct mitochondrial permeability transition pore inhibitor, reduced infarction in hearts from both wild-type and homozygous GSK-3 double knockin mice. Furthermore, in adult cardiac myocytes from GSK-3 double knockin mice, insulin exposure was still as effective as cyclosporin A in delaying mitochondrial permeability transition pore opening. Our results, which include a novel genetic approach, suggest that the inhibition of GSK-3 is unlikely to be the key determinant of cardioprotective signaling in either preconditioning or postconditioning in the mouse.
Insights
Glycogen synthase kinase-3 (GSK-3) inactivation is not the primary mechanism behind heart protection from preconditioning or postconditioning. Novel genetic mouse models show that GSK-3 inhibition is unlikely to be the key determinant of cardioprotective signaling.
Area of Science:
- Cardiovascular Research
- Molecular Cardiology
- Cellular Signaling
Background:
- Glycogen synthase kinase-3beta (GSK-3beta) inactivation is hypothesized to integrate cardioprotective pathways.
- GSK-3 inactivation is thought to prevent mitochondrial permeability transition pore (mPTP) opening.
Purpose of the Study:
- To investigate the role of GSK-3 in mediating cardioprotection using a novel genetic mouse model.
- To determine if GSK-3 inhibition is essential for preconditioning and postconditioning-induced myocardial protection.
Main Methods:
- Utilized a targeted mouse line with mutated GSK-3beta (Ser9) and GSK-3alpha (Ser21) to prevent inactivation.
- Applied preconditioning and postconditioning protocols to isolated perfused mouse hearts.
- Administered pharmacological GSK-3 inhibitors and cyclosporin A (a direct mPTP inhibitor).
- Assessed infarct size and mPTP opening in wild-type and GSK-3 mutant hearts.
Main Results:
- Both preconditioning and postconditioning reduced infarct size in wild-type and GSK-3 mutant mouse hearts.
- Pharmacological GSK-3 inhibition did not replicate conditioning-induced protection.
- Cyclosporin A and insulin effectively inhibited mPTP opening in GSK-3 mutant cardiac myocytes.
Conclusions:
- GSK-3 inactivation is unlikely to be the critical mediator of cardioprotection induced by preconditioning or postconditioning in mice.
- Mitochondrial permeability transition pore inhibition remains a key target for cardioprotection, independent of GSK-3 activity.

